Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCRX NASDAQ:CLDX NASDAQ:LXRX NASDAQ:ZBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$10.17+3.4%$8.99$6.00▼$10.94$2.50B0.555.70 million shs4.37 million shsCLDXCelldex Therapeutics$37.95-1.1%$32.48$19.72▼$39.16$3.01B0.91.20 million shs470,282 shsLXRXLexicon Pharmaceuticals$2.32$2.06$0.84▼$2.68$1.03B1.054.30 million shs2.22 million shsZBIOZenas BioPharma$26.45-2.9%$20.06$9.32▼$44.60$1.72B-0.961.01 million shs605,319 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals+3.35%+6.49%+20.93%+6.05%+13.69%CLDXCelldex Therapeutics-1.09%+1.36%+32.60%+21.05%+72.70%LXRXLexicon Pharmaceuticals0.00%-12.12%+21.47%+45.00%+154.95%ZBIOZenas BioPharma-2.86%+3.52%+51.40%+17.66%+163.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$10.17+3.4%$8.99$6.00▼$10.94$2.50B0.555.70 million shs4.37 million shsCLDXCelldex Therapeutics$37.95-1.1%$32.48$19.72▼$39.16$3.01B0.91.20 million shs470,282 shsLXRXLexicon Pharmaceuticals$2.32$2.06$0.84▼$2.68$1.03B1.054.30 million shs2.22 million shsZBIOZenas BioPharma$26.45-2.9%$20.06$9.32▼$44.60$1.72B-0.961.01 million shs605,319 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals+3.35%+6.49%+20.93%+6.05%+13.69%CLDXCelldex Therapeutics-1.09%+1.36%+32.60%+21.05%+72.70%LXRXLexicon Pharmaceuticals0.00%-12.12%+21.47%+45.00%+154.95%ZBIOZenas BioPharma-2.86%+3.52%+51.40%+17.66%+163.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCRXBioCryst Pharmaceuticals 2.73Moderate Buy$21.67113.04% UpsideCLDXCelldex Therapeutics 2.82Moderate Buy$49.3029.91% UpsideLXRXLexicon Pharmaceuticals 2.33Hold$4.5596.12% UpsideZBIOZenas BioPharma 2.56Moderate Buy$44.2967.43% UpsideCurrent Analyst Ratings BreakdownLatest LXRX, CLDX, BCRX, and ZBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2026BCRXBioCryst Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$32.006/30/2026BCRXBioCryst Pharmaceuticals Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$27.00 ➝ $29.006/24/2026ZBIOZenas BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/18/2026LXRXLexicon Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/15/2026CLDXCelldex Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.006/10/2026CLDXCelldex Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$38.00 ➝ $45.006/3/2026ZBIOZenas BioPharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/3/2026ZBIOZenas BioPharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/1/2026BCRXBioCryst Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)5/15/2026ZBIOZenas BioPharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/15/2026ZBIOZenas BioPharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$44.00(Data available from 7/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCRXBioCryst Pharmaceuticals$874.84M2.95$1.28 per share7.95($0.57) per share-17.84CLDXCelldex Therapeutics$1.54M1,934.22N/AN/A$7.93 per share4.79LXRXLexicon Pharmaceuticals$49.80M20.69N/AN/A$0.30 per share7.73ZBIOZenas BioPharma$10M166.98N/AN/A$4.51 per share5.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCRXBioCryst Pharmaceuticals$263.86M-$1.78N/A27.49N/A-51.71%-76.36%60.12%8/3/2026 (Estimated)CLDXCelldex Therapeutics-$258.76M-$4.26N/AN/AN/AN/A-50.72%-46.59%8/6/2026 (Estimated)LXRXLexicon Pharmaceuticals-$50.34M-$0.07N/AN/AN/A-37.46%-18.64%-11.79%8/5/2026 (Estimated)ZBIOZenas BioPharma-$377.74M-$8.47N/AN/AN/AN/A-99.99%-58.06%8/11/2026 (Estimated)Latest LXRX, CLDX, BCRX, and ZBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/3/2026Q2 2026BCRXBioCryst Pharmaceuticals$0.14N/AN/AN/A$185.69 millionN/A5/13/2026Q1 2026ZBIOZenas BioPharma-$1.4742-$1.46+$0.0142-$1.46$25.00 millionN/A5/7/2026Q1 2026CLDXCelldex Therapeutics-$1.1472-$1.18-$0.0328-$1.18$0.80 million$0.02 million5/7/2026Q1 2026LXRXLexicon Pharmaceuticals-$0.04-$0.0026+$0.0374N/A$9.79 million$21.10 million5/6/2026Q1 2026BCRXBioCryst Pharmaceuticals$0.06-$2.98-$3.04-$2.98$151.12 million$156.41 million4/13/2026Q4 2025ZBIOZenas BioPharmaN/A-$1.10N/A-$0.98$40.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/ACLDXCelldex TherapeuticsN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/AZBIOZenas BioPharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCRXBioCryst PharmaceuticalsN/A1.911.88CLDXCelldex TherapeuticsN/A8.928.92LXRXLexicon Pharmaceuticals0.2418.8018.77ZBIOZenas BioPharma1.0411.9411.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCRXBioCryst Pharmaceuticals85.88%CLDXCelldex TherapeuticsN/ALXRXLexicon Pharmaceuticals74.70%ZBIOZenas BioPharmaN/AInsider OwnershipCompanyInsider OwnershipBCRXBioCryst Pharmaceuticals3.80%CLDXCelldex Therapeutics5.20%LXRXLexicon Pharmaceuticals14.00%ZBIOZenas BioPharma22.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCRXBioCryst Pharmaceuticals530254.16 million244.51 millionOptionableCLDXCelldex Therapeutics15078.49 million74.41 millionOptionableLXRXLexicon Pharmaceuticals140444.20 million382.01 millionOptionableZBIOZenas BioPharmaN/A63.13 million49.24 millionN/ALXRX, CLDX, BCRX, and ZBIO HeadlinesRecent News About These CompaniesZenas BioPharma Inc ZBIOJune 27, 2026 | morningstar.comMZenas BioPharma (NASDAQ:ZBIO) Stock Rating Upgraded by Wall Street ZenJune 27, 2026 | americanbankingnews.comZenas BioPharma Announces Positive Phase 3 Obexelimab ResultsJune 24, 2026 | theglobeandmail.comZenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.June 21, 2026 | fool.comEcoR1 Capital LLC Acquires New Shares in Zenas BioPharma, Inc. $ZBIOJune 18, 2026 | marketbeat.comZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 17, 2026 | globenewswire.comPolar Capital Holdings Plc Makes New Investment in Zenas BioPharma, Inc. $ZBIOJune 17, 2026 | marketbeat.com321,983 Shares in Zenas BioPharma, Inc. $ZBIO Bought by NEXTBio Capital Management LPJune 14, 2026 | marketbeat.comZenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert SummitJune 11, 2026 | globenewswire.comZenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR ...June 2, 2026 | finance.yahoo.comZenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of MedicineJune 2, 2026 | globenewswire.comA Look At Zenas BioPharma (ZBIO) Valuation After Strong 1-Year Return And Recent Share Price WeaknessJune 1, 2026 | finance.yahoo.comZenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RDMay 28, 2026 | globenewswire.comZenas Biopharma Inc.May 26, 2026 | money.usnews.comZenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 ...May 19, 2026 | markets.businessinsider.comZenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 CongressMay 19, 2026 | globenewswire.comZenas BioPharma (NASDAQ:ZBIO) CEO Purchases $1,012,800.00 in StockMay 19, 2026 | insidertrades.comZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 18, 2026 | globenewswire.comZenas BioPharma Advances Phase 3 Orelabrutinib Trial in Tough MS SegmentMay 18, 2026 | tipranks.comWhy Zenas BioPharma (ZBIO) Is Down 7.7% After Reporting a Sharply Wider Quarterly Net LossMay 14, 2026 | uk.finance.yahoo.comZenas BioPharma Stock Short Interest Report | NASDAQ:ZBIO | BenzingaMay 13, 2026 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLXRX, CLDX, BCRX, and ZBIO Company DescriptionsBioCryst Pharmaceuticals NASDAQ:BCRX$10.17 +0.33 (+3.35%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$10.22 +0.05 (+0.48%) As of 04:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Celldex Therapeutics NASDAQ:CLDX$37.95 -0.42 (-1.09%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$38.08 +0.13 (+0.34%) As of 05:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Lexicon Pharmaceuticals NASDAQ:LXRX$2.32 0.00 (0.00%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$2.33 +0.01 (+0.22%) As of 04:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Zenas BioPharma NASDAQ:ZBIO$26.45 -0.78 (-2.86%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$26.52 +0.07 (+0.25%) As of 07/6/2026 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore KBR Insiders Are Buying While the Market Misreads Its Spinoff Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street AI Is Selling Off, But These 5 Stocks Could Benefit Next MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
